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Epidemiology of renal replacement therapy: International important observations on the health of the patients with
comparisons of renal replacement therapy. Renal replacement ESRD, the extent and accuracy of the data collected
therapy (RRT) remains the most important tool for all patients vary widely. For this reason, Kjellstrand [1] stated thatwith end-stage renal disease (ESRD) in the world. Patients
international comparisons of data on ESRD patients andare usually listed in the national renal registries which report
renal replacement therapy may not be valid becausedemographic data, incidence, prevalence and outcome. Differ-
ences in acceptance of the RRT, patient demographics, socio- of the differences in acceptance of the treatment, pat-
economic burdens and national health care legislature influ- ient demographics, socioeconomic burdens, and national
ence the validity of international comparisons of ESRD
health care legislation. Considering this important scien-therapy. For this reason, the renal registries decided to organize
tific bias, the renal registries decided to organize an inter-an international collaborative study group, the International
Federation of Renal Registries (IFRR), for improving the stan- national collaborative study group called the Interna-
dardization of renal databases and for promoting international tional Federation of Renal Registries (IFRR) to discuss
collaborative studies. Demographic data from renal registries different databases. The first meeting of the IFFR wasin 1996 showed that approximately 1,000,000 of ESRD patients
held in 1997 during the 14th International Congress ofreceived RRT throughout the world and approximately 200,000
Nephrology in Sydney, Australia, and the first reportnew patients started RRT. The different distribution of patients
in the world is strongly influenced by the level of gross domestic was published in the same year [2]. Delegates from the
product (GDP), since economical crisis may influence the num- Asian-Pacific Registry, Australian and New Zealand Di-
ber of patients starting RRT. The reported incidence and prev-
alysis and Transplant Registry (ANZDATA), Canadianalence values of ESRD patients in RRT from the renal regis-
Organ Replacement Registry (CORR), European Renaltries show these differences. The mortality rate of these patients
is notably influenced by the percentage of enrolled diabetic Association Registry (ERA-EDTA), Japanese Society
RRT patients. Therefore, important differences in outcome of for Dialysis Therapy (JSDT), Latin American Registry,
RRT depend on the underlying disease which is a determinant and the United States Renal Data System Registry
factor of prognosis. Other factors responsible for the outcome
(USRDS) participate in the IFRR. The duties of theare represented by dialysis dose, type of membrane, erythro-
federation include the development of a dialogue be-poietin and nutritional status.
tween renal registries for the improvement and standard-
ization of renal databases; the definition of a common
terminology, the definition of a common methodologyRenal replacement therapy (RRT) by hemodialysis,
for analyzing data and finally the promotion of interna-peritoneal dialysis, and renal transplantation became
tional collaborative studies.available in the 1960s; thereafter, a growing number of
patients undergoing treatment of end-stage renal disease
(ESRD) were listed in the renal registries. Dialysis con- DEMOGRAPHIC DATA
tinues to be the most frequent type of RRT because of
Table 1 shows the number of patients on RRT world-the low rate of renal transplantation, strictly related to
wide in 1996 and the number of new patients who startedinsufficient organ donation to meet demand. Renal trans-
RRT for the first time. Data have been obtained fromplantation is the best form of treatment for a limited
renal registries with .90% response rate (RR) fromnumber of ESRD patients.
dialysis facilities, registries with ,90% response rate,Although the use of data from renal registries permits
and from published papers (1999 pers. comm. from G.
Lee, Asian-Pacific Registry; A. Disney, ANZDATA; S.
Key words: renal registries, incidence, prevalence, outcome measures. Fenton, CORR; F. Berthoux, ERA-EDTA; K. Maeda,
Japanese Society for Dialysis Therapy; N. Mazzuchi, 2000 by the International Society of Nephrology
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Table 1. RRT patients world-wide as of December 31, 1996 registries are an under-representation of patients receiv-
ing RRT. Third, in addition to the quantity and qualityPrevalence Incidence Countries
of the therapy, access to the different forms of RRT isRegistry (RR . 90%)
ANZDATA 11,066 2,292 2 partly dependent on the health care system of the coun-
CORR 18,874 3,413 1 try. This explains why in some areas of the world inJSDT 167,192 28,409 1
which the GDP is low, a low percentage of subjectsUSRDS 282,847 73,091 1
Total 479,979 107,205 with ESRD receives RRT. On the other hand, in some
488,000a 108,000a countries with a high GDP, renal transplantation is lessRegistry (RR , 90%)
Asian Pacific 46,105 12,938 10 frequent because organ donation is low due to religious
ERA-EDTA 317,131 63,416 43 or social problems. Such variables cannot be easily ad-
Latin American 81,796 21,894 21
justed for in most statistical analyses. Finally, reportsIndian Ocean Soc. 767 125 4
Total 445,799 98,373 from the renal registries include ESRD patients receiv-
450,000a 102,000a ing RRT—either dialysis or renal transplantation—byNo registry
the first day of treatment. However, this is not consistentIndia 20,000a 2,000a 1
China 30,000a 4,000a 1 from registry to registry; for instance, the registry of
Others 20,000a 4,000a
the Japanese Society for Dialysis Therapy includes onlyTotal 70,000a 10,000a
Total 1,000,000a 220,000a dialyzed patients, while the USRDS registry considers
all ESRD patients treated with RRT by the 91st daya Estimated
because the Medicare system does not achieve complete
reporting of patients data before day 90. Thus, patients
who die before this time (early mortality within 90 days)Latin American Registry; and L. Agodoa, USRDS). For
are not accounted for by the USRDS. In addition, in allsome countries the number of RRT patients has been
renal registries world-wide, patients who die of ESRDestimated. In 1996, approximately 1,000,000 patients re-
before receiving RRT are not included, and data fromceived RRT (dialysis or renal transplant) in the world
the registries consequently do not express the true epide-and 200,000 new patients started RRT. There are several
miology of ESRD in those countries.limitations to this estimate because in the international
renal registries and in the countries with low gross do-
mestic product (GDP), some factors such as demography
INCIDENCEof the population, socioeconomic structures, organiza-
tion of health care systems, patient access to RRT, and Incidence represents the number of persons diagnosed
the response rate of dialysis facilities to the questionnaire with ESRD in a specific population in a given time pe-
influence the estimation of RRT population. These limits riod, usually a year. It is a useful measure for medical
were documented by Mazzuchi et al in the Latin Ameri- and epidemiological research that examines the causes
can Registry [3]. The most important factor, for the renal of the disease and the differences in how subpopulations
registries, which influences the collection of annual data, are affected by these causes. The annual incidence rate
is the response rate to the questionnaire. of treated ESRD patients is expressed by the number
The database of renal registries world-wide should of patients beginning RRT related to the annual general
validate the accuracy at the time of data collection, but population at the beginning of the year. It is expressed
four important, strictly-correlated factors may influence as a number of patients per million of population (pmp)
the quality of the data. First, the submission of the data per year. There is a bias of the incidence among the
may be mandatory and linked to the reimbursement of
renal registries because not all patients with ESRD are
treatments performed in dialysis facilities. The USRDS
included, as was mentioned in the discussion of demogra-registry works in this manner because Medicare only
phy above. In addition, the incidence of ESRD does notreimburses the cost of dialysis treatment after it receives
take into account those patients not treated; thereforepatient data, which are then supplied to the USRDS.
it does not measure the overall occurrence of ESRD.This system covers more than 93% of all patients treated
The incidence of ESRD patients on RRT continuesfor ESRD in the United States. Second, other registries
to increase world-wide. By considering the incidencework on the basis of voluntary submission of data. In such
rates of the four national renal registries with more thancases, only a few renal registries, such as the ANZDATA
90% of response rate to the questionnaire during theseregistry, CORR, and the Japanese Society for Dialysis
last four years (1994–1997), the number of new patientsTherapy receive data from more than 90% of all dialysis
pmp listed in USRDS and Japanese Registries is higherfacilities. Other voluntary national and international reg-
than in ANZDATA and CORR. The mean annual per-istries have a response rate to the questionnaire of the
dialysis centers lower than 90%. For these reasons some centage of increase is 7.6% of incidence rate in USRDS
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Fig. 1. Overall incidence rates in new ESRD patients per million popu-
lation. Symbols are: h, 1994; , 1995; , 1996; j, 1997. Fig. 2. Asian-Pacific Registry incidence data from selected countries
(response rate . 90%). Incidence rates are given as patients per million
population (pmp).
and 3.2–3.7% in the other three registries (Fig. 1). The
rates of newly treated ESRD patients vary from registry of time (period prevalence). Point prevalence indicates
to registry and may reflect differences in acceptance and the number of alive treated patients on a particular date,
referral patterns among countries. The likelihood of ac- usually December 31 of the year. It is the most common
ceptance into RRT program is influenced by many fac- definition of prevalence used by the renal registries.
tors such as age, gender, distance of home from dialysis Point prevalence is a useful measure for public health
facility, employment and transplantation program. The research, since it measures the overall burden of the
acceptance rates for incident patients continues to in- disease on the health care delivery system. Period preva-
crease in industrialized countries but not in those with lence differs from the above term because it counts the
low GDP. In fact, in 1998 a reduction in incidence of number of patients receiving RRT anytime during a par-
new RRT patients was reported in some Asian countries ticular interval of time, such as a calendar year. It is the
(Singapore and Taiwan) as a result of the economic crisis sum of the point prevalence on the first day of the year
in these areas of the world (Fig. 2), while a slight increase plus the incidence during the year. It is used less often
was observed in some Latin-American countries in the than point prevalence. Period prevalence is a useful mea-
last two years (Fig. 3). In countries with high GDP, the sure for cost analysis, since it indicates the total burden
mean age of incident patients is still increasing, due to of the disease over the course of the year. Its rate is
the above-average proportion of older patients starting related to the annual general population count prefera-
therapy [4]. About half of the new patients are over the bly in the middle of the year and is expressed as number
normal retirement age, and over the last decade there of patients per million population (pmp). For simplicity
has been at least a four-fold increase in the number of both incidence and prevalence are referred as rates.
patients entering dialysis over the age of 74 years [5]. A These two terms are adjusted to age, gender and other
growing proportion of the RRT population is over the conditions. The Japanese registry records the highest
age of 85 years. The pros and cons of RRT in patients mean prevalence rates (7.4%) during the last four
over 80 years of age are continuously discussed [6]. How- years (1994–1998) followed by the USRDS, CORR and
ever, elderly patients must be informed about the treat- ANZDATA (Fig. 4). This may be due to a better survival
ments offered. Specific recommendations will help them among ESRD patients and low transplant activity in
to decide whether to accept treatment, and the final Japan [7].
decision must be the patient’s alone, with no pressure In other registries where incidence rates of ESRD
to make choices on the grounds of financial limitations. patients in RRT are similar, in addition to patient demo-
graphics and transplant activity, a similar prevalence of
ESRD is observed (Figs. 5, 6, and 7).PREVALENCE
Prevalence represents the number of persons in a spe-
OUTCOME MEASUREScific population who have ESRD at a given point. Both
incidence rates of the disease and the survival rates in- Outcome research is a rapidly evolving field that incor-
fluence it. The prevalence includes patients who are new porates epidemiology, health service research, health
and those who are continuing RRT for ESRD. The prev- economics and psychometrics. The outcome measures
alence rate per million population is the prevalence count have evolved from simple dichotomous ones such as
divided by the population size in million on either a survival or occurrence of a clinical event to patient-ori-
ented measures such as satisfaction, quality of life andparticular date (point prevalence) or during an interval
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Fig. 3. Latin American Registry incidence data.
(A) Overall incidence. (B) Incidence rates
from selected countries (response rate .
90%).
due to differences in enrollment criteria or type of treat-
ment. It can be adjusted among prevalent patients and
differences in mortality could reflect innovations in treat-
ment that affect all patients being treated in that year.
Because large differences exist between countries on the
acceptance of ESRD patients it is difficult to interpret
observed differences in mortality rates. For dialysis pa-
tients factors influencing the mortality rate are repre-
sented by the type of disease causing ESRD, utilization
of treatment modalities, different health care system and
delivery. The USRDS registry excludes from some analy-Fig. 4. Overall prevalence rates (patients pmp). Symbols are: h,
1994; , 1995; , 1996; j, 1997. ses dialysis-unrelated deaths caused by AIDS, accidents
unrelated to treatment, and street drug overdoses. These
exclusions make the death rate more useful as a norm
for evaluating the care given to ESRD patients. The
functional status. The outcome measures, listed by Ep- adjusted annual death rates for all dialysis patients and
stein and Sherwood, are grouped into three important for all ESRD patients, prevalent at any time during
areas: clinical, characterized by clinical events, physio- each year, decreased progressively from 1989 to 1996
logic and metabolic measures and mortality; economic,
in USRDS registry but remains higher than that of
including direct and indirect medical measures; and hu-
other renal registries [9]. The crude mortality rate inmanistic, in which symptoms, quality of life, functional
ANZDATA in these last three years remained approxi-status and patient satisfaction are included [8]. The
mately 14% in dialysis patients and 7% in all ESRDchoice of outcome measures depends on the priorities
patients (A. Disney. ANZDATA, personal communica-of those examining the data. Clinicians are more inter-
tion, 1999) and ranged about 9% of dialysis patients inested in clinical and humanistic outcomes whereas pa-
the Japanese Registry [10]. Marcelli et al stated in atients may be preferentially interested in humanistic
recent paper that for international studies, it is necessarymeasures. Health plan administrators are more inter-
to develop a common standard data collection instru-ested in economic ones. Current renal registry manage-
ment in all ESRD registries including the recording ofment programs include a mixture of all measures.
comorbid conditions and their severity [11]. Other fac-The mortality rate is an important outcome measure
tors responsible for the death rate among ESRD patientsto characterize the impact of RRT on the ESRD patient
are represented by the dose of dialysis [12], shift frompopulation in the national and international renal regis-
cellulose to synthetic membranes [13], administration oftries. The crude annual mortality rate is expressed by
erythropoietin dose [14], dialysis facility differences [15],the number of deaths divided by the product of the
mode of dialysis therapy [16], hypertension [17], cardio-number of ESRD patients and the time on treatment
vascular diseases [18], Ca-P metabolism [19], and malnu-during the year (patient-years). It is expressed by the
trition [20].number of deaths per 100 patient-years at risk. Death
Important differences in outcome of RRT patientsrates can be adjusted for age categories, time spent on
depend on the underlying disease, which is a determinantRRT and mortality of general population (standardized
mortality ratio). Difference in mortality rate could be factor of prognosis. It is well known that diabetes reduces
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Fig. 5. Asian Pacific Registry prevalence data.
(A) Overall prevalence. (B) Prevalence rates
from selected countries (response rate .
90%).
Fig. 6. Latin American Registry prevalence
data. (A) Overall prevalence. (B) Prevalence
rates from selected countries (response rate .
90%).
Fig. 7. ERA-EDTA Registry prevalence data.
(A) Overall prevalence. (B) Prevalence rates
from 15 countries of the European Union (re-
sponse rate 5 89%).
the survival of ESRD patients; the prognosis is particu- receiving RRT in comparison with other countries [22].
For this reason, diabetes was the most common causelarly severe for elderly patients. Some large differences
exist among countries in the utilization of dialysis modal- of ESRD in the United States in 1996, whereas glomeru-
lonephritis was the primary cause of ESRD in otherities and in acceptance of patients, particularly for dia-
betics and elderly subjects. Therefore, it is difficult to registries’ patients (Table 2). Nevertheless, an increased
incident number of diabetic patients has been evidencedinterpret observed differences in mortality rates among
registries [21]. A valid comparison of data in national in the last four years in all national and international
registries. The relatively high risk of death of these pa-registries should be attempted for the primary diagnosis.
The USRDS registry in the last report showed an in- tients is further increased by their poor nutritional status
and by factors related to their predialysis care. In fact,creased number of incident ESRD patients with diabetes
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Table 2. The most common diseases responsible for ESRD in the dialysis than hemodialysis patients. Patient-reported
renal registries (1996).a
general health tended to decrease with age. Non-diabet-
USRDS CORR ANZDATA JSDT ics had better health than diabetic hemodialysis patients.
Incidence The majority of patients were retired or disabled. One-
Diabetes 41.7 28.2 18.6 33.8 half of patients were driven by someone and one quarter
Hypertension 25.7 9.9 9.7 6.5
drove themselves. After this study, in collaboration withGlomerulonephritis 10.5 16.1 34.5 38.2
Point prevalence Amgen, the University Renal Research and Education
Diabetes 32.4 23.0 29.6 21.7 Association (URREA) located in Ann Arbor, Michigan,
Hypertension 24.7 9.3 12.2 3.9
USA organized three important international dialysisGlomerulonephritis 17.6 20.3 22.0 53.5
outcomes and practice patterns studies (DOPPS) ina Values are expressed as percent of ESRD patients in RRT
three continents of the world. The US-DOPPS involves
160 dialysis facilities as a national representative sample
of US. The I-DOPPS randomly selected 100 dialysis facil-
a prospective study on enrolled hemodialysis patients ities in five European countries (France, Germany, Italy,
evidenced that at the start of dialysis diabetic patients Spain and the United Kingdom); 20 in each country. The
had more left ventricular hypertrophy, ischemic heart Japan-DOPPS recruited 60 dialysis facilities in Japan as
disease and cardiac failure than non-diabetics [23]. These a national representative sample. These three observa-
findings suggest that these events in the predialytic life tional and prospective studies follow a common design,
should be notably reduced. protocol and analysis of the data for comparing practice
The understanding of patient demographics and the patterns and their effects on patient outcomes. These
proportion of patients with high mortality rate in predial- studies should lead to improve the general health of
ysis life should be taken into account on the data base hemodialysis patients throughout the world. The ran-
of renal registries. It is possible to attempt to statistically domized choice of dialysis facilities and the accurate
adjust differences in patient characteristics and comorbid instruction of the nursing staff and physicians participat-
conditions in a second phase. Consequently, interna- ing in the study will eliminate bias normally present in
tional comparative studies of survival require multivari- the collection of data from retrospective studies. There-
ate analysis with appropriate adjustment for differences fore, the adequate data collection methodology and the
in patient demographics, known risk factors and comor- accuracy of information will give important insights on
bid conditions. RRT in the world. Future collaborations among regis-
tries with more than 90% of response rate of the ques-
tionnaire from the dialysis facilities are well accepted forFUTURE COLLABORATIVE STUDIES
prospective clinical studies.
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